Effects of the addition of beta2-agonist tulobuterol patches to inhaled corticosteroid in patients with asthma

Allergology International

Volumn 58, Issue 4, 2009, Pages 509-518

  Hozawa, Soichiro ^a,b   Haruta, Yoshinori ^c   Terada, Michikazu ^a   Yamakido, Michio ^c  

^a Hiroshima Res and Devmt Center   (Japan)

^b MAZDA HOSPITAL   (Japan)

^c HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Airway inflammation; Bronchial asthma; Bronchial hyperresponsiveness; Inhaled corticosteroids; Tulobuterol patch

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHACHOLINE; THEOPHYLLINE; TULOBUTEROL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EOSINOPHIL; EXPIRATORY RESERVE VOLUME; FEMALE; HEART PALPITATION; HUMAN; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; SPUTUM; THERAPY EFFECT; TREATMENT RESPONSE; TREMOR;

EID: 75449088655     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.2332/allergolint.08-OA-0060     Document Type: Article

References (27)

1. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001;107:783-9.
2. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24.
3. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8.
4. Pauwels RA, Löfdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997;337:1405-11.
5. Ukena D, Harnest U, Sakalauskas R et al. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997;10:2754-60.
6. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337:1412-8.
7. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
8. National Heart, Lung, and Blood Institute. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Revised 2006. Available from: http://www.ginasthma.org.
9. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program(NAEPP), Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma . Bethesda, MD: National Institutes of Health, 1997; NIH Publication No. 97-4051.
10. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J 1994;7:579-91.
11. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-8.
12. Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double-blind, randomised, comparative trial. BMJ 2003;327:891.
13. Uematsu T, Nakano M, Kosuge K, Kanamaru M, Nakashima M. The pharmacokinetics of the beta 2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Eur J Clin Pharmacol 1993;44:361-4.
14. Asthma Guideline Committee of the Japanese Society of Allergology. [Asthma Prevention and Management Guideline 2006, Japan ]. Tokyo: Kyowa Kikaku, 2006(in Japanese).
15. Tamura G, Miyamoto T, Nakashima O et al. Effect of transdermal tulobuterol added to inhaled corticosteroids in asthma patients. Allergol Int 2005;54:615-20.
16. Tsukioka K. [Peak Expiratory Flow in Normal, Healthy Japanese Subjects]. Revised ed. Tokyo: Kyowa Kikaku Tsushin, 2002(in Japanese).
17. Hozawa S, Haruta Y, Ishioka S, Yamakido M. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Respir Crit Care Med 1995;152:1198-202.
18. Pin I, Gibson PG, Kolendowicz R et al. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax 1992;47:25-9.
19. Hozawa S, Tanaka H, Terada M et al. Tulobuterol patch, transdermal LABA, improves small airways resistance in elderly asthma treated with inhaled corticosteroids. Am J Respir Crit Care Med 2008;177:A611.
20. Eickelberg O, Roth M, Lörx R et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-10.
21. Adcock IM, Stevens DA. Molecular interactions between corticosteroids and beta2-agonists. In: Kummer F (ed). Treatment of Asthma: The Long-Acting Beta2-Agonists. New York: Springer Med Wein, 1998;15-40.
22. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002;19:182-91.
23. Yamaguchi T, Nagata M, Miyazawa H, Kikuchi I, Hagiwara K, Kanazawa M. Tulobuterol, a β2-agonist, attenu ates eosinophil adhesion to endothelial cells. Allergol Int 2005;54:283-8.
24. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998;158:924-30.
25. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2003;167:1232-8.
26. Panina-Bordignon P, Mazzeo D, Lucia PD et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513-9.
27. Kume H, Kondo M, Ito Y, Suzuki R, Yamaki K, Takagi K. Effects of sustained-release tulobuterol on asthma control and beta-adrenoceptor function. Clin Exp Pharmacol Physiol 2002;29:1076-83.